PharmaNest Launches Its Digital Pathology Spatially Resolved, Quantitative Tissue Panels to Quantify Tissue Injury and Inflammation in the Context of Fibrotic Conditions

June 22, 2023 3:00 PM

PharmaNest, a leader in high resolution quantitative Digital Pathology and Artificial Intelligence, announces today the launch new quantitative tissue panels to properly quantify tissue injury and inflammation in the context of multiple fibrotic conditions, from discovery models to clinical development. Such spatially resolved datasets can be fused with other spatially resolved biology methods.PRINCETON, NJ / ACCESSWIRE / June 22, 2023 /...

Read more

Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science

June 22, 2023 9:25 AM

DehydraTECH-CBD now featured in eight published, peer-reviewed papersKELOWNA, BC / ACCESSWIRE / June 22, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its groundbreaking research utilizing DehydraTECH-processed cannabidiol ("DehydraTECH-CBD") has now been published in eight peer-reviewed articles in six different publications.The most recent...

Read more

Ondine Biomedical Inc. - Photodisinfection Cuts COVID in Meat Processing

June 22, 2023 4:00 AM

Non-regulatory announcementNewly published results show treatment with Ondine's nasal photodisinfection dramatically reduced COVID-19 rates at Canadian meat processing plantWeekly nasal photodisinfection of 1,500 workers in a meat processing plant in Western Canada reduced infection to only 3 positive PCR tests out of over 21,000 administered during a seven-month period (December 2020 to May 2021). The expected provincial rate was 1,344 positive...

Read more

VoluMetrix Awarded Grant From Pennsylvania Pediatric Medical Device Consortium to Advance the NIVA Technology for Pediatric Patients

June 21, 2023 9:00 AM

NASHVILLE, TEN / ACCESSWIRE / June 21, 2023 / VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital monitoring to enhance well-being, announced today that it has been awarded a grant from the CHOP-based Pennsylvania Pediatric Medical Device Consortium, funded by the U.S. Food and Drug Administration, to accelerate the development of the NIVA Pediatric Monitor, a device designed to provide volume...

Read more

Organicell Welcomes Harry Leider, MD, MBA as its New CEO

June 21, 2023 8:30 AM

FORT LAUDERDALE, FL / ACCESSWIRE / June 21, 2023 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, is pleased to announce the appointment of Harry L. Leider, MD, MBA as its new Chief Executive Officer (CEO). Dr. Leider has a distinguished background as a highly innovative healthcare executive and entrepreneur with...

Read more

Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study

June 21, 2023 7:00 AM

BOSTON, MA / ACCESSWIRE / June 21, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer indications, announced that partner AstraZeneca yesterday communicated to Pieris its decision to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4 receptor...

Read more

Year-end Report 2022/2023 - Commercial Agreements Signed in the US and Europe!

June 21, 2023 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 21, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)SEK tQ4 22/23Q4 21/22May-April 22/23May-April 21/22Net sales5871,0823,3832,045Operating profit (loss)-37,208-19,132-110,457-60,101Earnings per share-0.81-0.67-3.18-2.11Number of shares at the end of the period45,741,45028,488,37245,741,45028,488,372Cash and cash equivalents at the end of the period114,32789,792114,32789,792Significant events...

Read more

BioInvent Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

June 21, 2023 1:45 AM

Well-tolerated infusions, no dose limiting toxicities or serious adverse eventsStable disease observed in six patients so far; efficacy to be further explored in Phase 2aLUND, SWEDEN / ACCESSWIRE / June 21, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer...

Read more

Celcuity Set to Join Russell 2000 and 3000 Indexes

June 20, 2023 9:02 AM

MINNEAPOLIS, MN / ACCESSWIRE / June 20, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, is set to join the Russell 2000® and 3000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, according to the most recent list of additions posted June 16.Annual Russell indexes...

Read more

PharmaNest to Present Six Digital Pathology Abstracts at the International Liver Congress-EASL 2023, Including Liver Related Clinical Outcomes Prediction Results in NASH

June 19, 2023 1:00 AM

PharmaNest, a leader in high resolution, single-fiber, quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest Ph-FCS continuous fibrosis biomarker for the quantification of the severity of fibrosis and prognostics of liver related clinical events in NASH.PRINCETON, NJ / ACCESSWIRE / June 19, 2023 / PharmaNest Inc, a leader in high resolution quantitative Digital Pathology and Artificial...

Read more

Navigating the Inflation Reduction Act (IRA) with Former FDA Commissioner, Mark McClellan

June 16, 2023 4:50 PM

IRVINE, CA / ACCESSWIRE / June 16, 2023 / The 2022 Inflation Reduction Act (IRA) is poised to be the most revolutionary change to US drug pricing in decades, rapidly ascending as a top policy priority for pharmaceutical manufacturers and insurers, large and small. Innopiphany LLC., a life science consultancy and expert network FirstThought, will co-host an informational webinar on the IRA with former FDA commissioner Mark McClellan. This...

Read more

Late-Breaking Results of a Preclinical Efficacy Study Presented at ENDO 2023 Show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia

June 16, 2023 2:05 PM

GERMANTOWN, MD / ACCESSWIRE / June 16, 2023 / Seraxis today announced late-breaking results of an ongoing study evaluating the efficacy of SRE pancreatic clusters in a type 1 diabetes model at the Endocrine Society Annual Scientific Meeting ENDO held in Chicago, IL. The poster (#10117) is available at www.seraxis.com.Results from an ongoing type 1 diabetes efficacy study with Seraxis SRE (Synthetic Replacement Endocrine) clusters (SR1423)...

Read more

NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division

June 16, 2023 12:40 PM

CLEVELAND, OH and BANGKOK, THAILAND / ACCESSWIRE / June 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced a partnership with Thailand-based CKN Ventures Limited, a multifaceted clinical and commercial healthcare platform, to expand clinical data set access in Southeast Asia to enhance and accelerate personalized therapeutics and treatment protocols. This...

Read more

Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study

June 16, 2023 9:10 AM

Blood glucose levels reduced by 19.9% with DehydraTECH-CBDImprovements in kidney function also demonstratedKELOWNA, BC / ACCESSWIRE / June 16, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to report upon additional findings from its diabetes animal study DIAB-A22-1, and also provide updates on two other applied R&D programs.Diabetes:...

Read more

L-Nutra Launches Revolutionary Healthcare Program for Diabetes Remission

June 16, 2023 9:00 AM

SANTA MONICA, CA / ACCESSWIRE / June 16, 2023 / L-Nutra, a leading company in the field of Longevity and Food as Medicine, is delighted to announce the launch of its groundbreaking program, L-Nutra Health for Diabetes, at the ENDO 2023 Conference in Chicago. This unique Program is based on a published study and is specifically designed to assist individuals with type 2 diabetes with the goal to achieve remission, empowering them to reduce or...

Read more

Nano Imrad Technology (NIT) Announces Availability of Actinium-225, Pioneering a New Era of Cancer Treatment

June 15, 2023 4:00 PM

Beginning in the second quarter of 2023, NIT will provide Actinium-225 in millicurie quantities, marking a significant step forward in cancer treatmentDALLAS, TX / ACCESSWIRE / June 15, 2023 / Nano Imrad Technology (NIT), an innovative medical research and development company, is pleased to announce the availability of Actinium-225 for medical research and treatment. Beginning in the second quarter of 2023, NIT will provide Actinium-225 in...

Read more

TISSIUM Obtains a Non-Dilutive Financing of €4.2 Million Within the Framework of the "FRANCE 2030" Plan

June 15, 2023 12:00 PM

PARIS, FRANCE / BOSTON, MA / ACCESSWIRE / June 15, 2023 / TISSIUM, a private medtech specializing in the development of programmable biomorphic polymers for tissue reconstruction, announces it has obtained a non-dilutive financing of €4.2 million from Bpifrance as part of the "France 2030" plan to extend its production capacity for "large volume" syringes.As TISSIUM continues to enrich its product platform in new therapeutic indications, it...

Read more

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

June 15, 2023 8:00 AM

TORONTO, ON / ACCESSWIRE / June 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today the assignment of the name "daniluromer" for its first-in-class anti-inflammatory drug candidate.Daniluromer is a non-steroidal anti-inflammatory compound that inhibits secretory phospholipase 2 (sPLA2) pro-inflammatory enzymes. The sPLA2 enzyme family plays...

Read more

With an Eye on the Future, Biolog Launches Odin

June 15, 2023 5:00 AM

HAYWARD, CA / ACCESSWIRE / June 15, 2023 / Biolog, Inc., a leading provider of microbial polyphasic analysis, today announced the launch of the Odin™ system, an all-in-one cellular phenotyping and microbial identification platform. Odin is compatible with all Biolog assays and is available now.Until today, Biolog's OmniLog® platform was the gold standard for researchers who want actionable insights on microbial metabolic phenotypes....

Read more

Cerillo Unveils Co-Culture Duet System for Real-Time Observation of Microbial Interaction Studies

June 14, 2023 10:00 AM

The company will showcase the first wireless, scalable, off-the-shelf co-culture solution at ASM Microbe 2023 in Houston, TX June 16th-18thCHARLOTTESVILLE, VA / ACCESSWIRE / June 14, 2023 / Cerillo, a biotechnology company at the forefront of developing advanced research platforms for the study of the microbiome, will host demonstrations of the company's new co-culture duet system at ASM Microbe 2023 from June 16-18th in Houston, Texas at booth...

Read more